InvestorQ : How do you see Divi developing its own input process for COVID medicines?
Arya Nanda made post

How do you see Divi developing its own input process for COVID medicines?

Answer
user profile image
Anjana Aiyar answered.
1 week ago


There have been some interesting developments sat Divi’s Laboratories, the fast growing pharma company based out of Hyderabad. Recently, Divi’s Laboratories has fine tuned the process to make COVID-19 drugs purely from domestic inputs source from India.

This tweaked process will enable Divi to produce hydro-chloroquine and Favipiravir. While the former is popularly used for its malaria effectiveness, the latter is generally used for less acute versions of COVID sickness.

The said drugs made entirely from Indian inputs are already approved for COVID treatment by the DCGI, the nodal regulatory body controlling pharmaceutical industry in India. Divi has also the process to make 4 critical intermediates of Remdesivir.

The company has invested Rs.1800 crore last year in these facilities and is likely to make more self reliant in managing the pharma industry supply chains. This will avoid an embarrassment like last year when Indian pharma industry faced a roadblock due to disruption of Chinese supply chains.